StockData
Oruka Therapeutics, Inc. logo

Oruka Therapeutics, Inc. (ORKA) stock

ORKANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$95.74−0.58 (-0.60%)

Close on Nov 18, 2026Market cap $6.34BP/E –Yield –

Oruka Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Oruka Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$155.08M. For fiscal 2025 it was -$122.05M. The highest annual figure on record is -$4.32M in fiscal 2012.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$122.05M–
FY2023Dec 31, 2023-$7.30M–
FY2022Dec 31, 2022-$10.60M–
FY2021Dec 31, 2021-$19.34M–
FY2020Dec 31, 2020-$9.77M–
FY2019Dec 31, 2019-$5.81M–
FY2018Dec 31, 2018-$8.12M–
FY2017Dec 31, 2017-$18.71M–
FY2016Dec 31, 2016-$16.61M–
FY2015Dec 31, 2015-$11.46M–
FY2014Dec 31, 2014-$9.69M–
FY2013Dec 31, 2013-$6.94M–
FY2012Dec 31, 2012-$4.32M–
FY2011Dec 31, 2011-$7.36M–
FY2010Dec 31, 2010-$9.18M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$50.11M–
Q1 FY2026Mar 31, 2026-$36.43M–
Q4 FY2025Dec 31, 2025-$34.43M–
Q3 FY2025Sep 30, 2025-$34.11M–
Q2 FY2025Jun 30, 2025-$28.43M–
Q1 FY2025Mar 31, 2025-$25.09M–
Q3 FY2024Sep 30, 2024-$29.45M–
Q2 FY2024Jun 30, 2024-$21.49M–
Q1 FY2024Mar 31, 2024-$2.48M–
Q4 FY2023Dec 31, 2023-$1.59M–
Q3 FY2023Sep 30, 2023-$1.94M–
Q2 FY2023Jun 30, 2023-$1.97M–
Q1 FY2023Mar 31, 2023-$1.80M–
Q4 FY2022Dec 31, 2022-$1.55M–
Q3 FY2022Sep 30, 2022-$2.55M–
Q2 FY2022Jun 30, 2022-$3.22M–
Q1 FY2022Mar 31, 2022-$3.28M–
Q4 FY2021Dec 31, 2021-$5.68M–
Q3 FY2021Sep 30, 2021-$4.72M–
Q2 FY2021Jun 30, 2021-$4.84M–
Q1 FY2021Mar 31, 2021-$4.10M–
Q4 FY2020Dec 31, 2020-$5.13M–
Q1 FY2020Mar 31, 2020-$1.34M–
Q4 FY2019Dec 31, 2019-$1.28M–
Q3 FY2019Sep 30, 2019-$1.25M–
Q2 FY2019Jun 30, 2019-$1.51M–
Q1 FY2019Mar 31, 2019-$1.78M–
Q4 FY2018Dec 31, 2018-$1.53M–
Q3 FY2018Sep 30, 2018-$1.66M–
Q2 FY2018Jun 30, 2018-$2.16M–
Q1 FY2018Mar 31, 2018-$2.77M–
Q4 FY2017Dec 31, 2017-$4.30M–
Q3 FY2017Sep 30, 2017-$4.48M–
Q2 FY2017Jun 30, 2017-$5.56M–
Q1 FY2017Mar 31, 2017-$4.38M–
Q4 FY2016Dec 31, 2016-$4.29M–
Q3 FY2016Sep 30, 2016-$4.71M–
Q2 FY2016Jun 30, 2016-$3.94M–

More Oruka Therapeutics figures

See a number that looks wrong?